This study is in progress, not accepting new patients
Safety and Effectiveness of Experimental IMC-C103C With or Without Atezolizumab for Advanced MAGE-A4-positive Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Davis
- Dates
- study startestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Immunocore Ltd
- ID
- NCT03973333
- Phase
- Phase 1/2 Solid Tumor Research Study
- Study Type
- Interventional
- Participants
- Expecting 144 study participants
- Last Updated